Literature DB >> 20418034

The HER3/ErbB3 receptor: a promising target in cancer drug therapy.

C Desbois-Mouthon1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20418034     DOI: 10.1016/j.gcb.2010.03.002

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


× No keyword cloud information.
  4 in total

Review 1.  The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.

Authors:  Sean P Kennedy; Jordan F Hastings; Jeremy Z R Han; David R Croucher
Journal:  Front Cell Dev Biol       Date:  2016-08-22

2.  Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies.

Authors:  Gianluca Lopez; Giulia Lazzeri; Alessandra Rappa; Giuseppe Isimbaldi; Fulvia Milena Cribiù; Elena Guerini-Rocco; Stefano Ferrero; Valentina Vaira; Alessio Di Fonzo
Journal:  Genes (Basel)       Date:  2020-07-24       Impact factor: 4.096

3.  HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Authors:  Andrew R Green; Fabrício F T Barros; Tarek M A Abdel-Fatah; Paul Moseley; Christopher C Nolan; Alice C Durham; Emad A Rakha; Stephen Chan; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2014-04-06       Impact factor: 4.872

4.  Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Authors:  Corina Buta; Eva Benabou; Marie Lequoy; Hélène Régnault; Dominique Wendum; Fatiha Meratbene; Hamza Chettouh; Lynda Aoudjehane; Filomena Conti; Yves Chrétien; Olivier Scatton; Olivier Rosmorduc; Françoise Praz; Laetitia Fartoux; Christèle Desbois-Mouthon
Journal:  J Exp Clin Cancer Res       Date:  2016-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.